Human medicines European public assessment report (EPAR): Darzalex, daratumumab, Date of authorisation: 20/05/2016, Revision: 2, Status: Authorised
Human medicines European public assessment report (EPAR): Zeposia, ozanimod, Date of authorisation: 20/05/2020, Revision: 6, Status: Authorised
Cancer Medicines Forum: February 2024, Online, European Medicines Agency, Amsterdam, the Netherlands, 26 February 2024
Big data
Guidance on real-world evidence provided by EMA: support for regulatory decision-making
Minutes of the 122nd meeting of the Management Board, 13-14 December 2023
Human medicines European public assessment report (EPAR): Eladynos, abaloparatide, Date of authorisation: 12/12/2022, Revision: 4, Status: Authorised
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 8-11 April 2024
Emend (aprepitant) supply shortage
Pharmaceutical quality of inhalation and nasal products - Scientific guideline